[Histopathological Diagnosis of Non-alcoholic and Alcoholic Fatty Liver Disease. Grade 2 Consensus-based Guidelines]
Affiliations
Both alcoholic (AFL) and non-alcoholic fatty liver (NAFL) are characterized by lipid deposition in hepatocytes. The diagnosis of steatosis is made when lipid deposition exceeds 5% of hepatocytes, while involvement of more than 50% is called "fatty liver ". An additional inflammatory reaction leads to alcoholic (ASH) or non-alcoholic steatohepatitis (NASH). Steatohepatitis is present when both inflammatory infiltrates of mixed cells in the small liver lobules as well as liver cell injury in terms of ballooning can be detected.Liver biopsy represents the "gold standard" for confirming diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease.The differential diagnosis of ASH-NASH cannot be made on the basis of histological criteria alone. Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a "Brunt Score" or "NAS" (NAFLD activity score), providing the basis on which to decide whether or not steatohepatitis is present.People at increased risk of developing a fatty liver possess an increased risk of developing chemotherapy-associated steatohepatitis (CASH).Histologically, pediatric NASH differs from adult NASH and is often only clinically manifest through a mild if persistent elevation in transaminases.
Jesper D, Klett D, Schellhaas B, Pfeifer L, Leppkes M, Waldner M IEEE J Transl Eng Health Med. 2020; 8:1800409.
PMID: 32617199 PMC: 7326151. DOI: 10.1109/JTEHM.2020.3001488.
Laparoscopic Sleeve Gastrectomy on the Horizon as a Promising Treatment Modality for NAFLD.
Salman M, Salman A, Abdelsalam A, Atallah M, Shaaban H, El-Mikkawy A Obes Surg. 2019; 30(1):87-95.
PMID: 31372873 DOI: 10.1007/s11695-019-04118-6.
Sanchez-Pareja A, Clement S, Peyrou M, Spahr L, Negro F, Rubbia-Brandt L World J Gastroenterol. 2016; 22(14):3735-45.
PMID: 27076758 PMC: 4814736. DOI: 10.3748/wjg.v22.i14.3735.
Ulbrich E, Fischer M, Manoliu A, Marcon M, Luechinger R, Nanz D PLoS One. 2015; 10(11):e0141691.
PMID: 26554709 PMC: 4640707. DOI: 10.1371/journal.pone.0141691.
[Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?].
Munding J, Luttges J, Esposito I, Tannapfel A Pathologe. 2014; 35(5):509-18.
PMID: 24981895 DOI: 10.1007/s00292-012-1712-7.